CA-MOBILEIRON
8.5.2019 15:02:09 CEST | Business Wire | Press release
MobileIron (NASDAQ:MOBL) introduces the industry’s first mobile-centric, zero trust security platform. MobileIron's mobile-centric strategy allows for continuous enforcement and protection of data, both on the device and on the network, with comprehensive correlation between the critical signals for zero trust: user, device, apps, networks, and threats. This makes the world’s most ubiquitous product – the mobile device – your ID and secure access to the enterprise. This platform goes beyond identity management and gateway approaches by utilizing a more comprehensive set of attributes before granting access.
With mobile devices as your ID, organizations replace the password with a secure and frictionless alternative, ushering in a new era of user authentication. MobileIron is introducing a revolutionary zero sign-on experience built on the company’s leading unified endpoint management (UEM) platform and powered by the MobileIron Access solution.
Zero sign-on completely eliminates passwords as the method for user authentication, replacing single sign-on, which still requires at least one username and password. MobileIron paved the way for a zero sign-on enterprise with its Access product in 2017, which enabled zero sign-on to cloud services on managed devices. Today’s announcement extends this capability, making passwordless access to cloud services available from any device, managed or unmanaged, using the mobile device as the user’s secure ID.
“Mobile is the center of our universe, both personally and professionally. With that comes a need for a mobile-centric enterprise-grade security solution,” said Simon Biddiscombe, CEO, MobileIron. “We are delivering that solution – making the mobile device your ID and access to the enterprise. And we didn’t stop there. We are eliminating passwords for any device, whether managed or unmanaged, because we think single sign-on is one sign-on too many.”
Zero sign-on solves three problems inherent in passwords. As Forrester Research analysts Andras Cser and Merritt Maxim explain: “First, passwords represent a security risk because they can be easily hacked, and password reuse can start an avalanche of breaches. Second, password-related reset costs generate significant operational support costs. Third, password authentication is often the source of a bad user experience, especially in mobile environments” (Forrester: Understand The State Of Identity And Access Management, 2018 To 2019 ) . Zero sign-on eliminates the pain and expense of traditional user credentials, replacing it with a seamless, secure authentication alternative.
A passwordless enterprise has been an unfulfilled promise for years. In fact, according to an April 2019 IDG survey of security decision makers, 86% would do away with passwords if they could. The same survey found that nearly 9 out of 10 security leaders believe that, in the near future, mobile devices will serve as the digital ID to access enterprise services and data.
The MobileIron security platform is built on the foundation of award-winning and industry-leading unified endpoint management (UEM) capabilities with additional zero trust-enabling technologies, including zero sign-on (ZSO), multi-factor authentication (MFA), and mobile threat defense (MTD). Together, they enable a seamless, secure user experience by ensuring only authorized users, devices, apps, and services can access business resources.
MobileIron’s vision is to revolutionize enterprise authentication with a mobile ID and zero sign-on experience from any device, any OS, any location, to any service. Turning vision into reality, MobileIron’s zero sign-on for unmanaged devices will be available in June 2019 on iOS devices. These capabilities will extend to Android devices later this year. For more information, visit here .
About MobileIron
MobileIron is redefining enterprise security with the industry’s first mobile-centric, zero trust platform built on the foundation of unified endpoint management (UEM) to secure access and protect data across the perimeter-less enterprise. Over 17,000 customers, including the world’s largest financial institutions, intelligence agencies, and other highly regulated companies rely on MobileIron to enable a seamless and secure user experience by ensuring only authorized users, devices, apps, and services can access business resources. For more information, visit www.mobileiron.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005145/en/
Contact:
Marjaneh Ravai MobileIron mravai@mobileiron.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
